摩根大通周一在一份投资者报告中表示,在第二季度财报发布后,礼来(NYSE:LLY)股票是其美国大型生物制药公司中的"首选"。 "虽然orforglipron三期肥胖症减重数据略低于预期,但我们认为该产品在市场中仍有明确定位,而礼来的核心注射型胰高血糖素样肽-1受体激动剂产品线仍处于最佳位置,"分析师写道。 他们补充说,"在上周的抛售之后,礼来股票目前仅以约29倍/21倍的保守2025/2026年...
Source Link摩根大通周一在一份投资者报告中表示,在第二季度财报发布后,礼来(NYSE:LLY)股票是其美国大型生物制药公司中的"首选"。 "虽然orforglipron三期肥胖症减重数据略低于预期,但我们认为该产品在市场中仍有明确定位,而礼来的核心注射型胰高血糖素样肽-1受体激动剂产品线仍处于最佳位置,"分析师写道。 他们补充说,"在上周的抛售之后,礼来股票目前仅以约29倍/21倍的保守2025/2026年...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.